Perspective Therapeutics Reports 75% 18-Month Progression-Free Survival in Bamzireotide Trial Subgroup

• Perspective Therapeutics presented additional Phase 1/2a bamzireotide trial results in advanced neuroendocrine tumors at NANETS on Nov. 5, 2026.
• Results showed sustained disease control, supporting a focus on gastroenteropancreatic neuroendocrine tumors with SSTR2 expression in all target lesions.
• The treatment remained well tolerated, with no dose-limiting toxicities or treatment-related discontinuations.
• The subgroup findings could guide patient selection in a registration-enabling study under discussion with regulators.
• An end-of-Phase 2 meeting is targeted for first-quarter 2027; Phase 3 initiation that year depends on FDA feedback and preparatory work.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611052010PRIMZONEFULLFEED9871976) on November 06, 2026, and is solely responsible for the information contained therein.